Pasithea Therapeutics Launches Phase 1/1B Study of PAS-004
The excitement is palpable at Pasithea Therapeutics as they announce the start of a pivotal Phase 1/1B study for PAS-004, aimed at treating adult patients with neurofibromatosis type 1 (NF1). The company anticipates dosing the first patient in mid-2025, marking a significant step forward in developing innovative therapies for this challenging condition.
Understanding the Phase 1/1B Study
This clinical study is designed to examine the safety and tolerability of PAS-004, a next-generation macrocyclic MEK inhibitor. The trial will also explore the pharmacokinetics (how the drug is processed in the body) and pharmacodynamics (the effects of the drug on the body) of PAS-004.
Key Details of the Trial
PAS-004 will be given as a daily 4mg tablet. The primary objective is to assess how this treatment works for patients suffering from both plexiform neurofibromas and cutaneous neurofibromas—tumors resulting from NF1. The study will not only evaluate initial anti-tumor activity but will also identify the most effective dosage for future Phase 2 trials.
Site Activations and Expansions
The first trial site has been activated at the Royal North Shore Hospital in Sydney, Australia, with plans to open additional sites in South Korea and the United States. This multi-site approach aims to expedite patient enrollment and broaden the study’s reach, providing diverse data.
Research Support and Collaboration
To ensure the trial's success, Pasithea has partnered with Novotech (Australia) Pty Limited, a noted clinical research organization. Furthermore, the company stands to benefit from the Australian R&D Tax Incentive, which could refund up to 48.5% of eligible study-related costs, enhancing the financial feasibility of the research.
Expert Insights into the Study Design
Dr. Rebecca Brown, M.D., Ph.D., a member of Pasithea’s Scientific Advisory Board, emphasizes the study's comprehensive design. By focusing on both plexiform and cutaneous neurofibromas, the study aims to provide a thorough understanding of PAS-004's effects, which could lead to improved treatment compliance for NF1 patients.
Looking Ahead: What This Means for Pasithea
Dr. Tiago Reis Marques, the CEO of Pasithea, highlights the significance of this trial in the company’s trajectory. With recent financing enabling this critical research, Pasithea is eager to generate initial data that could pave the way for FDA marketing approval. He believes PAS-004 may become a first-choice therapy for NF1-related conditions, thanks to its promising tolerability reported in previous studies.
About Pasithea Therapeutics Corp.
Pasithea is a clinical-stage biotechnology company dedicated to the development of novel therapies for central nervous system disorders, RASopathies, and tumors driven by the MAPK pathway. Their focus on innovative treatment options highlights the company's commitment to addressing unmet medical needs.
Frequently Asked Questions
What is the purpose of the PAS-004 Phase 1/1B study?
The study aims to evaluate the safety, tolerability, and effectiveness of PAS-004 in treating adult patients with neurofibromatosis type 1.
When will the first patient be dosed?
The first patient in the study is expected to be dosed in mid-2025.
Where is the first trial site located?
The first trial site is located at the Royal North Shore Hospital in Sydney, Australia.
What financial support is Pasithea expecting?
Pasithea anticipates a cash refund of up to 48.5% of eligible study costs through the Australian R&D Tax Incentive.
What conditions does PAS-004 target?
PAS-004 is being evaluated for its effectiveness in treating both plexiform and cutaneous neurofibromas in patients with NF1.
